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urine samples before surgery, after anesthesia induction, 
upon stent placement, before aortic cross-clamping (AXC), 
1 and 2 h after AXC, at the end of surgery, 4 h after surgery, 
and on postoperative days (PODs) 1, 2, and 3, for measure-
ment of L-FABP. We obtained serum samples before sur-
gery, immediately after surgery, and on PODs 1, 2, and 3, 
for measurement of SCr. We also plotted receiver-operating 
characteristic (ROC) curves to identify cutoff laboratory 
values for predicting the onset of AKI.
Results With EVAR, urinary L-FABP was significantly 
increased 4 h after the procedure (P = 0.014). With open 
repair, urinary L-FABP increased significantly to its maxi-
mum by 2 h after AXC (P = 0.007). With AKI, SCr signifi-
cantly increased (P < 0.001, P = 0.001) by POD 2. ROC 
analysis showed urinary L-FABP to be more sensitive than 
SCr for early detection of AKI.
Conclusion Urinary L-FABP appears to be a sensitive 
biomarker of AKI in patients undergoing abdominal aortic 
repair.
Keywords Urinary liver-type fatty-acid-binding protein · 
Acute kidney injury · Abdominal aortic repair
Introduction
Acute kidney injury (AKI) is common after cardiovascular 
surgery, sometimes requiring postoperative hemodialysis, 
and is associated with increased morbidity and mortality 
[1]. AKI occurs after abdominal aortic aneurysm repair 
surgery in >30 % of cases and leads to a prolonged hospi-
tal stay [2]. Both open abdominal aortic aneurysm repair 
and infrarenal aortic cross-clamping (AXC) decrease renal 
blood flow and increase renal vascular resistance. These 
changes, which indicate diminished global perfusion with 
Abstract 
Purpose Acute kidney injury (AKI) is common after car-
diovascular surgery and is usually diagnosed on the basis of 
the serum creatinine (SCr) level and urinary output. How-
ever, SCr is of low sensitivity in patients with poor renal 
function. Because urinary liver-type fatty-acid-binding pro-
tein (L-FABP) reflects renal tubular injury, we evaluated 
whether perioperative changes in urinary L-FABP predict 
AKI in the context of abdominal aortic repair.
Methods Study participants were 95 patients who under-
went endovascular abdominal aortic aneurysm repair 
(EVAR) and 42 who underwent open repair. We obtained 
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redistribution of renal blood flow toward the cortical com-
partment, persist for at least 1 h after release of the aortic 
clamp [3–5]. Infrarenal AXC produces profound and sus-
tained alterations in renal hemodynamics and may be par-
ticularly harmful in patients with impaired renal function or 
when it is prolonged [3].
Endovascular abdominal aortic aneurysm repair 
(EVAR), performed with intra-arterial contrast enhance-
ment, has become an important treatment for infrarenal 
abdominal aortic aneurysm. Although prospective studies 
have shown better renal outcomes with EVAR than with 
open repair, the long-term durability and safety of stent 
grafting remain unclear [6–8]. EVAR requires intra-arte-
rial administration of contrast medium, which can impair 
renal function and even lead to end-stage renal disease 
[9–11]. Although the incidence of contrast-induced AKI is 
low (2 %) in the general population, it is high (5–10 %) in 
patients at risk for kidney disease, such as those with car-
diovascular disease [12, 13]. Early diagnosis and treatment 
of AKI may be essential for improved perioperative renal 
outcomes after both EVAR and open repair. Biomarkers 
are used effectively in the diagnosis of AKI, with assay of 
serum creatinine (SCr) being the gold standard. However, 
SCr is of low sensitivity in patients with poor renal func-
tion or low muscle mass [14, 15]. Several new biomarkers 
of kidney injury have been investigated, both experimen-
tally and clinically, with liver-type fatty-acid-binding pro-
tein (L-FABP) being a promising candidate [16]; it is rec-
ognized as the most useful alternative biomarker of kidney 
injury. Matsui et al. described urinary L-FABP as an early 
predictor of AKI after cardiac surgery [17]. In addition, 
Kamijo et al. showed urinary L-FABP to be an excellent 
biomarker for clinical prediction and monitoring of renal 
disease [18]. Several studies have shown the usefulness of 
urinary L-FABP for the detection of AKI after cardiac sur-
gery [19] and contrast-induced nephropathy [20].
We conducted a prospective study with two aims: (1) 
to evaluate the perioperative changes in urinary L-FABP 
that occur with EVAR and open abdominal aortic aneu-
rysm repair, and (2) to examine the usefulness of urinary 
L-FABP for predicting AKI after either type of abdominal 
aortic repair.
Methods
The study protocol was approved by the Institutional 
Review Board of St. Marianna University School of Medi-
cine (No 1966), Kawasaki, Japan, and registered University 
Hospital Medical Information Network (UMIN) Clinical 
Data Registry (ID 000006584). Written informed consent 
was obtained from all patients enrolled in the study.
Study design
We conducted a two-part prospective study in a university 
hospital setting: one part to investigate AKI associated with 
EVAR and the other to investigate AKI associated with 
open repair. Consecutive patients scheduled for EVAR 
(n = 95) or open repair (n = 42) between October 2011 
and June 2015 were enrolled. Each patient’s surgeon chose 
between EVAR and open repair by considering the patient’s 
age and the type of abdominal aortic aneurysm in the 
absence of any concern regarding the patient’s tolerance for 
study procedures. Excluded from the study were patients 
undergoing dialysis or requiring emergency surgery.
EVAR study protocol
Anesthesia
No premedication or epidural anesthesia was administered 
to any patient in the EVAR group. General anesthesia was 
induced with remifentanil and propofol. Tracheal intuba-
tion was facilitated with rocuronium, and general anesthe-
sia was maintained with sevoflurane in an air–oxygen mix-
ture and remifentanil.
Sample collection
Urine samples (10 ml) were obtained before surgery, after 
anesthesia induction, upon stent placement, at the end 
of surgery, 4 h after surgery, and on postoperative days 
(PODs) 1, 2, and 3 for measurement of urinary L-FABP 
and urinary albumin. Urine samples were centrifuged at 
1000 g for 5 min at 4 °C and stored at −80 °C until analy-
sis. In addition, serum samples were obtained before sur-
gery, immediately after surgery, and on PODs 1, 2, and 3 to 
measure serum creatinine (SCr).
Open‑repair study protocol
Anesthesia
No premedication was administered to any patient in the 
open-repair group. All patients in this group received epi-
dural anesthesia before the surgery. An epidural catheter 
was inserted via the Th9/10, Th10/11, or Th11/12 interver-
tebral space. General anesthesia was induced with remifen-
tanil and propofol. Tracheal intubation was facilitated with 
rocuronium. Anesthesia was maintained with sevoflurane in 
an oxygen–air mixture and remifentanil. Levobupivacaine 
(0.125 or 0.25 %) was administered via epidural catheter 
during the surgery. Dopamine, prostaglandin E1, and carp-
eritide were infused continuously during surgery.
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Sample collection
Urine samples (10 ml) were obtained before surgery, after 
anesthesia induction, before aortic cross-clamping (AXC), 
1 and 2 h after AXC, at the end of surgery, 4 h after sur-
gery, and on PODs 1, 2, and 3 for measurement of urinary 
L-FABP and urinary albumin. These urine samples were 
prepared and stored as described above. In addition, serum 
samples were obtained before surgery, immediately after 
surgery, and on PODs 1, 2, and 3 to measure SCr.
Clinical monitoring of EVAR and open‑repair patients
During the first 48 h postoperative period, we monitored 
patients for AKI as defined according to AKI network crite-
ria [21]. We also monitored patients’ estimated glomerular 
filtration rate (eGFR) at the start of this study, which was 
calculated according to the Japanese-coefficient-modified 
Chronic Kidney Disease Epidemiology Collaboration 
equation: eGFR = 194× (creatinine)−1.094 × (age)−0.287×
(0.739 if female) [22].
Assay of urinary L‑FABP, urinary albumin, and SCr
Urinary L-FABP levels were determined by enzyme-linked 
immunosorbent assay (ELISA) with use of the human 
L-FABP ELISA kit (CMIC, Tokyo, Japan). Urinary albu-
min was measured by immunonephelometry. SCr was 
measured by an enzymatic method.
Statistical analyses
Study variables are expressed as median [interquartile 
range (IQR)]. Between-group (AKI vs. non-AKI; EVAR 
vs. open repair) differences were analyzed using the Mann–
Whitney U test or chi-square test, as appropriate. One-way 
analysis of variance (ANOVA), followed by Dunnett’s post 
hoc test, was used for multiple comparisons. Receiver-
operating characteristic curves (ROCs) were plotted to 
identify cutoff laboratory values for predicting AKI onset. 
Univariate analysis was used to select the clinical risk fac-
tor for the occurrence of AKI and the characteristics show-
ing a significant difference between AKI and non-AKI 
groups. Following univariate analysis, significant unad-
justed predictors with P < 0.05 were used in a multivariate 
logistic regression analysis. Multivariate logistic regression 
analysis was performed using a forward selection method. 
All statistical analyses were performed with IBM SPSS 
Statistics, version 21.0 (IBM, Tokyo, Japan). P < 0.05 was 
considered significant for all analyses.
Results
EVAR study
AKI developed postoperatively in nine (9.5 %) of the 95 
patients enrolled in the EVAR study: stage 1 AKI in eight 
patients and stage 2 AKI in one patient. None required post-
operative renal replacement therapy (RRT). Body weight 
(P = 0.03) and body mass index (BMI) (P = 0.001) were 
significantly lower, diabetes mellitus (P = 0.049) and non-
steroidal anti-inflammatory drug (NSAID) use (P = 0.002) 
were significantly more prevalent, and duration of anes-
thesia (P = 0.046) and length of hospital stay (P = 0.005) 
were significantly longer in the AKI group than in the 
non-AKI group (Table 1). Before surgery, after anesthesia 
induction, and upon stent placement, urinary L-FABP level 
was high and was significantly increased (P = 0.014) in the 
AKI group at 4 h after surgery; it decreased over the three 
PODs (Fig. 1).
SCr and urinary albumin did not change in the non-
AKI group during the perioperative period; however, in 
the AKI group, it increased significantly on PODs 2 and 
3 (P = 0.000 and P = 0.011, respectively; Fig. 1). Mul-
tivariate logistic regression analysis performed for both 
groups showed preoperative urinary L-FABP level to be 
a predictor of postoperative AKI [odds ratio (OR) 6.76; 
confidence interval (CI) 1.76–25.94, P = 0.005; Table 2]. 
BMI was also shown to be a predictor factor. The cut-
off preoperative urinary L-FABP level was 9.0 μg/g Cr 
(Table 3).
ROC analysis
The biomarker with the largest area under the curve (AUC) 
for predicting AKI onset was urinary L-FABP at the fol-
lowing time points: before surgery, after anesthesia induc-
tion, upon stent placement, and 4 h after surgery; AUCs 
were 0.83, 0.81, 0.79, and 0.75, respectively (Table 4). 
Urinary L-FABP cutoff values at different time points for 
EVAR are shown in Table 3.
Open‑repair study
AKI developed postoperatively in 13 (31.0 %) of the 42 
patients enrolled in the open-repair study and was stage 
1 in all of them. No patient required postoperative RRT. 
Male sex (P = 0.000) was more prevalent, age (P = 0.025) 
was greater, and preoperative ischemic heart disease 
(P = 0.016) more prevalent among open-repair patients in 
the AKI than in the non-AKI group (Table 5).
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In open-repair patients in whom AKI developed, urinary 
L-FABP levels were significantly increased to their maxi-
mum by 2 h after AXC (P = 0.007). They decreased gradu-
ally thereafter to POD 3 (Fig. 2). SCr levels were signifi-
cantly increased immediately after surgery and on PODs 1, 
2, and 3 (P = 0.010, 0.001, 0.001, and 0.002, respectively; 
Fig. 2). Urinary albumin levels were significantly increased 
2 h after AXC, 4 h after surgery, and on PODs 1, 2, and 3 
(P = 0.009, 0.008, 0.002, 0.002, and 0.010, respectively; 
Fig. 2). Results of multivariate logistic regression analy-
sis for both AKI and non-AKI groups showed urinary 
L-FABP at 2 h post-AXC and SCr at POD2 to be predictors 
of postoperative AKI (OR 1.58, CI 1.13–2.21, P = 0.007; 
OR 64.0, CI 4.03–1016.2, P = 0.003; Table 6). The cutoff 
urinary L-FABP level at 2 h post-AXC was 173.0 μg/g Cr 
(Table 7).
Suprarenal AXC was applied in eight patients who 
underwent open repair; AKI developed in five (63 %), and 
Table 1  Patient characteristics 
and clinical outcomes in EVAR 
study
Data are expressed as median (interquartile range) or number (%)
EVAR endovascular aortic repair, AKI acute kidney injury, BMI body mass index, ASA American Society 
of Anesthesiologists, ACE inhibitor angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor 
blocker, NSAID nonsteroidal anti-inflammatory drug, Ca calcium channel,  Cr creatinine, SCr serum cre-
atinine, eGFR estimated glomerular filtration rate, RRT renal replacement therapy
a eGFR was calculated according to the Japanese coefficient-modified Chronic Kidney Disease Epidemiol-
ogy Collaboration equation: eGFR = 194 × (creatinine)−1.094 × (age)−0.287 × (0.739 if female)22
Non–AKI (n = 86) AKI (n = 9) P value
Sex (M/F) 70/16 8/1
Age (years) 78 (73–83) 78 (75–82) 0.949
Body weight (kg) 60 (53–68) 51 (48–61) 0.030
BMI (kg/m2) 23 (21–25) 20 (17–21) 0.001
ASA status (II/III) 67/19 5/4 0.138
Comorbidity, n (%)
  Diabetes mellitus 9 (10) 3(33) 0.049
 Hypertension 69 (80) 9 (100) 0.141
 Ischemic heart disease 33 (38) 3 (33) 0.787
 Chronic kidney disease 18 (21) 3 (33) 0.394
Concomitant medications, n (%)
 Ca inhibitor 51 (59) 7 (78) 0.297
 ACE inhibitor/ARB 38 (44) 4 (44) 0.988
 Statin 31 (36) 2 (22) 0.407
 Diuretic 8 (9) 1 (11) 0.860
 NSAID 0 (0) 1 (11) 0.002
 Smoking history 41 (48) 5 (56) 0.802
Preoperative urinary L-FABP (μg/g Cr) 5 (3.3–7.9) 14.1 (6.5–32.9) 0.002
Preoperative urinary albumin (mg/g Cr) 13.0 (7.9–33.6) 40.7 (16.4–59.9) 0.016
Preoperative SCr (mg/dl) 0.86 (0.77–1.01) 0.77 (0.63–1.14) 0.644
Preoperative eGFRa (ml/min) 63.1 (51.1–69.1) 57.5 (48.7–87.3) 0.854
General anesthesia 86 9
General anesthesia with epidural 0 0
Duration of anesthesia (min) 208 (185–234) 225 (220–290) 0.046
Duration of surgery (min) 128 (105–155) 145 (133–210) 0.069
Fluids infusion (ml) 1500 (1213–1800) 1650 (1300–2000) 0.337
Estimated blood loss (ml) 78 (39–143) 114 (76–148) 0.230
Contrast media (ml) 118 (100–160) 143 (116–226) 0.138
Operative and postoperative details
 Mechanical ventilation, n (%) 0 (0) 0 (0)
 Length of hospital stay (days) 13 (12–14) 17 (14–23) 0.005
 RRT required upon discharge 0 (0) 0 (0)
 In-hospital death 0 (0) 0 (0)
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peak urinary L-FABP concentration was 8410 μg/g Cr 
(6050–10,995 μg/g Cr). Infrarenal AXC was applied in the 
other five AKI patients (15 %) who underwent open repair; 
peak urinary L-FABP concentration in these patients was 
90 μg/g Cr (25–212 μg/g Cr).
ROC analysis
The biomarker with the largest AUC for predicting AKI 
onset was urinary L-FABP at 2 h after AXC, at the end 
of surgery, and 4 h after surgery; AUCs were 0.77, 0.75, 
and 0.76, respectively (Table 8). We determined urinary 
L-FABP cutoff values at different time points for EVAR 
and open repair, as shown in Table 7.
Differences in patient characteristics and surgical 
outcomes between EVAR and open repair
Median age of the open-repair patients was 69 years 
(IQR 65–75 years) and that of the EVAR patients was 
78 years (IQR 74–83 years). The median hospital stay of 
the open-repair patients was 19 days (IQR 16–25 days) 
and 13 days (IQR 12–15 days) for EVAR patients. Pre-
operative ischemic heart disease was significantly more 
prevalent in the open-repair than in the EVAR group 
(P = 0.030). The incidence of AKI was greater in the 
open-repair than in the EVAR group (31.0 vs. 9.5 %, 
respectively), increase in urinary L-FABP in open-repair 
patients was greater than in EVAR patients, and peak 
Fig. 1  Changes in urinary 
L-FABP, urinary albumin, and 
SCr in EVAR. Acute kidney 
injury (AKI; solid line) and 
non-AKI groups (dashed line). 
L-FABP liver-type fatty acid-
binding protein, SCr serum 
creatinine, EVAR endovascular 
aneurysm repair, Pre-op preop-
erative value, After induction 
value after induction of anesthe-
sia, Post-op immediate postop-
erative value, 4 h post-op value 
4 h after the operation, POD 
postoperative day. *P < 0.05 vs. 
non-AKI group at the same time 
point; †P < 0.05 vs. respective 
preoperative level in the same 
(AKI) group; ‡P < 0.05 vs. 
respective preoperative level in 
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urinary L-FABP level occurred earlier in the open-repair 
group than in the EVAR group. Hospital stays were sig-
nificantly longer for open-repair patients than for EVAR 
patients (P < 0.001).
Discussion
The most important results of this study were that preop-
erative urinary L-FABP was a good predictor of AKI after 
EVAR, and 2 h post-AXC urinary L-FABP was a good pre-
dictor of AKI after open repair. Our data show that urinary 
Table 2  Multivariate logistic regression analyses for AKI in the 
EVAR group
AKI acute kidney injury, EVAR endovascular aneurysm repair, OR 
odds ratio, CI confidence interval, BMI body mass index, NSAID non-
steroidal anti-inflammatory drug, L-FABP liver-type fatty-acid-bind-
ing protein, SCr serum creatinine, POD postoperative day
Variable Multivariate analysis
OR 95 % CI P value
BMI 0.51 0.31–0.84 0.008
Diabetes mellitus 1.46 0.89–2.39 0.138
NSAID 5.85 0.00–0.00 1.000
Length of hospital stay 1.13 0.76–1.67 0.553
Urinary L-FABP pre-operation 6.76 1.76–25.94 0.005
Urinary L-FABP after induction 0.65 0.05–9.19 0.746
Urinary L-FABP stent placement 10.6 0.59–190.9 0.109
Urinary L-FABP 4 h postoperation 0.96 0.24–3.83 0.957
SCr POD2 115.9 0.72–18,548.3 0.066
Table 3  Urinary L-FABP levels predictive of AKI in the EVAR study
L-FABP liver-type fatty-acid-binding protein, AKI acute kidney 
injury, EVAR endovascular aneurysm repair, PPV positive predictive 
value, NPV negative predictive value, POD postoperative day, Cr cre-
atinine 
Time point Cutoff value 
(μg/g Cr)
Sensitivity Specificity PPV NPV
Preoperation 9.0 0.67 0.82 0.63 0.85
After anesthe-
sia induction
5.9 0.89 0.61 0.51 0.93
At stent place-
ment
16.3 0.78 0.80 0.64 0.89
Postoperation 9.2 0.89 0.57 0.48 0.92
4 h postopera-
tion
87.8 0.56 0.92 0.76 0.82
POD1 68.1 0.44 0.87 0.63 0.78
POD2 28.1 0.56 0.74 0.48 0.79
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L-FABP is a useful biomarker for early AKI detection after 
abdominal aortic aneurysm repair, whether EVAR or open 
repair. In patients in whom AKI developed after either pro-
cedure, the rise in urinary L-FABP occurred earlier than the 
rise in SCr. Ueta et al. reported AKI-associated increases 
in SCr, neutrophil gelatinase-associated lipocalin (NGAL), 
and L-FABP 2–6 h after EVAR [23]. They also found uri-
nary Cr-corrected NGAL (NGAL/Cr) to be the best predic-
tive marker for AKI [23]. Because AKI occurred only in 
their thoracic EVAR (TEVAR) group, the TEVAR proce-
dure did not appear to affect renal blood flow differently 
from the EVAR procedure. Because our study used EVAR, 
we postulated that the cutoff urinary L-FABP level would 
be lower in the Ueta et al. study than in our study. Mori 
et al. observed that low levels of urinary L-FABP during 
hypothermic surgery for thoracic aortic aneurysm repair 
preceded the development of AKI [24]. Although urinary 
L-FABP was 62.1 ng/mg Cr in their AKI group, it was 
Table 5  Patient characteristics 
and clinical outcomes in the 
open-repair study
Data are expressed as median (interquartile range) or number (%)
AKI acute kidney injury, BMI body mass index, ASA American Society of Anesthesiologists, ACE inhibitor 
angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, NSAIDs nonsteroidal anti-
inflammatory drugs, Cr creatinine, SCr serum creatinine, eGFR estimated glomerular filtration rate, RRT 
renal replacement therapy, AXC aortic cross-clamping
a eGFR was calculated according to the Japanese coefficient-modified Chronic Kidney Disease Epidemiol-
ogy Collaboration equation: eGFR = 194 x (creatinine)−1.094 × (age)−0.287 × (0.739 if female)22
Non–AKI group (n = 29) AKI group (n = 13) P value
Sex (M/F) 26/3 12/1  <0.001
Age (years) 67 (64–72) 72 (69–78) 0.025
Body weight (kg) 61 (56–74) 68 (64–69) 0.187
BMI (kg/m2) 23 (21–25) 24 (24–26) 0.094
ASA status (II/III) 21/8 7/6 0.486
Comorbidity, n (%)
 Diabetes mellitus 2 (7) 3 (23) 0.134
 Hypertension 24 (92) 12 (92) 0.414
 Ischemic heart disease 13 (45) 11 (85) 0.016
 Chronic kidney disease 7 (24) 5 (38) 0.342
Concomitant medications, n (%)
 Ca inhibitor 17 (59) 8 (62) 0.859
 ACE inhibitor/ARB 17 (59) 8 (62) 0.859
 Statin 14 (48) 5 (38) 0.555
 Diuretic 2 (7) 2 (15) 0.386
 NSAID 1 (3) 0 (0) 0.498
 Smoking history 16 (55) 7 (54) 0.936
Preoperative urinary L-FABP (μg/g Cr) 4.1 (2.3–7.0) 4.4 (2.9–11.9) 0.863
Preoperative urinary albumin (mg/g Cr) 9.9 (6.4–13.8) 20 (8.3–69.3) 0.128
Preoperative SCr (mg/dl) 0.85 (0.75–1.06) 0.92 (0.85–1.31) 0.268
Preoperative eGFRa (ml/min) 67.3 (52.7–77.9) 62.3 (44.8–68.7) 0.196
General anesthesia 0 0
General anesthesia with epidural 29 13
Duration of anesthesia (min) 470 (410–585) 580 (500–640) 0.084
Duration of surgery (min) 345 (261–445) 443 (350–499) 0.077
Duration of AXC (min) 66 (55–88) 58 (46–95) 0.624
Fluids infusion (ml) 5560 (4300–6750) 5560 (4100–6890) 0.924
Estimated blood loss (ml) 2620 (1620–3926) 2343 (2179–3835) 0.765
Operative and postoperative details
 Mechanical ventilation, n (%) 0 (0) 2 (29)
 Length of hospital stay (days) 19 (16–28) 20 (17–24) 0.917
 RRT required upon discharge 0 (0) 0 (0)
 In-hospital death 0 (0) 0 (0)
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1130 ng/mg Cr in their non-AKI group after termination 
of deep hypothermic circulatory arrest. They proposed 
that urinary L-FABP plays a role in kidney protection [24]. 
However, while urinary L-FABP levels were higher in their 
non-AKI group than in their AKI group, levels ranged 
more widely in the latter group. In addition, if Mori et al. 
had measured urinary L-FABP at several time points after 
surgery rather than only before and after cardiopulmo-
nary bypass, their study results may have been different. 
Recently, Parr et al. reported that urinary L-FABP, but not 
urinary NGAL or urinary kidney-injury-molecule 1 (KIM-
1), predicted poor AKI outcomes [25]. Our finding that uri-
nary L-FABP increases earlier than SCr after AKI agrees 
with this latter report [25].
Hypoxic events, such as ischemic–reperfusion injury, 
cause the release of L-FABP from proximal tubular epi-
thelial cells, correlating with the severity of renal injury; 
hence, urinary L-FABP level increases immediately after 
tubular damage. Because of low reuptake, L-FABP from 
the proximal renal tubules is the main source of urinary 
L-FABP; serum L-FABP does not increase after injury 
[26, 27]. Furthermore, Nakamura et al. demonstrated that 
serum L-FABP levels do not reflect urinary L-FABP levels 
in patients with sepsis [27].
Mori et al. reported that the difference in the patterns of 
urinary NGAL increase and urinary L-FABP increase after 
cardiac surgery results from differences in the mechanism 
of urinary secretion [28]. NGAL is filtered by glomeruli 
Fig. 2  Changes in urinary 
L-FABP, urinary albumin and 
SCr in OR. Acute kidney injury 
(AKI; solid line) and non-AKI 
groups (dashed line). Pre-
op preoperative value, After 
induction value after induction 
of anesthesia, AXC value after 
aorta cross-clamping, Post-op 
immediate postoperative value, 
4 h post-op value 4 h after oper-
ation, POD postoperative day, 
L-FABP liver-type fatty-acid-
binding protein, SCr serum 
creatinine, OR open repair 
*P < 0.05 vs. the non-AKI 
group at the same time point; 
†P < 0.05 vs. the respective 
preoperative level in the same 
(AKI) group; ‡P < 0.05 vs. the 
respective preoperative level in 
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and reabsorbed by proximal tubules, with only 0.1–0.2 % 
remaining in the urine [28]. In the AKI setting, various 
stresses increase NGAL in the circulation through neutro-
phil activation, and the increased amount of NGAL is fil-
tered in glomeruli. Some NGAL molecules are reabsorbed 
by the damaged proximal tubules, whereas others are 
excreted. Therefore, increased urinary NGAL is due mainly 
to impaired renal reabsorption, [29], and it takes longer for 
the NGAL levels than for urinary L-FABP levels to increase.
Furthermore, in patients with urinary tract infection (UTI), 
median urinary angiotensinogen (AGT) levels were sig-
nificantly increased, but urinary proteins NGAL, L-FABP, 
N-acetyl-beta-D glucosaminidase (NAG) beta 2-microglobulin 
(BMG), serum AGT, and creatinine levels did not differ sig-
nificantly between groups [30]. This report showed that uri-
nary L-FABP did not increase in UTIs. To the contrary, urinary 
NGAL was significantly increased in patients with UTI com-
pared with that in healthy controls. Increased urinary NGAL 
indicates the presence of inflammatory processes in the urinary 
tract of adults [31] and is not a specific biomarker of AKI.
Urinary L-FABP increased earlier in our patients who 
underwent open repair than in those who underwent EVAR. 
This difference can be attributed to differences in renal tubu-
lar insult associated with EVAR and open repair. Abdominal 
AXC in open repair decreases and causes a shift in renal 
blood flow [3, 4], which may in turn cause a significant 
reduction in proximal tubular blood flow and lead to tubu-
lar epithelial cell hypoxia. Such hypoxia promotes L-FABP 
secretion into the urine. The decrease in renal blood flow 
and shift in the distribution of intrarenal blood flow occurs 
quickly after AXC. Proximal tubular ischemic–reperfusion 
injury causes AKI during the period of open repair. AXC 
decreases renal blood flow, and renal ischemia induces 
endothelial dysfunction and decreases production of vaso-
dilatory substances such as nitric oxide. After ischemia, 
blood flow decreased to 60 % of preischemic levels in 
superficial cortex and to 16 % in the outer medulla, but it 
increased to 125 % of control values in the inner medulla 
[5]. This decrease in blood flow to the outer medulla dimin-
ishes oxygen and nutrient delivery to tubules in this region, 
thus increasing the risk of cell injury [5]. Contrast-induced 
nephropathy (CIN) is the main cause of AKI in the context of 
EVAR [32]. Itoh et al. reported that contrast medium causes 
apoptosis of renal tubular cells [33]; Geenen et al. speculated 
that contrast medium led to tubular necrosis in CIN [13].
In addition, the EVAR procedure may induce thrombosis 
and embolism, leading to AKI. Urinary L-FABP increased ear-
lier in our patients who underwent open repair than in patients 
who underwent EVAR. Furthermore, the increase in urinary 
L-FABP was less with EVAR than with open repair, indicating 
that the degree of injury in EVAR was less. The hemodynamic 
change seems to be greater during open repair than during 
EVAR, and this change causes further deterioration of tubular 
Table 6  Results of multivariate logistic regression analyses for AKI 
in the open-repair group
AKI acute kidney injury, OR odds ratio, CI confidence interval, 
L-FABP liver-type fatty-acid-binding protein, Cr creatinine, SCr 
serum creatinine, POD postoperative day
Variable Multivariate analysis
OR 95 % CI P value
Sex 1.13 0.00–969.6 0.971
Age 1.51 0.95–2.42 0.085
Ischemic heart disease 0.78 0.44–1.38 0.389
Urinary L-FABP 2 h post-AXC 1.58 1.13–2.21 0.007
Urinary L-FABP postoperation 0.56 0.12–2.63 0.103
Urinary L-FABP 4 h postoperation 0.50 0.06–3.97 0.515
SCr postoperation 0.00 0.00–87.0 0.103
SCr POD1 13.4 0.00–1.15 0.824
SCr POD2 64.0 4.03–1016.2 0.003
Urinary albumin (10 mg/g Cr) 2 h 
postAXC
1.00 1.00–1.00 0.402
Table 7  Urinary L-FABP levels 
predictive of AKI in the open-
repair study
L-FABP liver-type fatty-acid-binding protein, AKI acute kidney injury, AXC aorta cross-clamping, PPV 
positive predictive value, NPV negative predictive value, POD postoperative day, Cr creatinine
Time point Cutoff value (μg/g Cr) Sensitivity Specificity PPV NPV
Preoperation 12.7 0.25 0.81 0.12 0.91
After anesthesia induction 9.9 0.42 0.69 0.12 0.92
Pre-AXC 5.6 0.83 0.42 0.13 0.96
1 h post-AXC 37.2 0.50 0.79 0.20 0.94
2 h post-AXC 173.0 0.67 0.83 0.30 0.96
Postoperation 32.3 0.92 0.54 0.17 0.98
4 h postoperation 348.5 0.50 0.92 0.40 0.95
POD1 112.1 0.62 0.83 0.28 0.95
POD2 48.6 0.54 0.83 0.25 0.95
POD3 19.5 0.85 0.61 0.19 0.97
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blood flow and leads to severe renal damage. The increase in 
urinary L-FABP in open repair involving suprarenal AXC was 
greater than that in open repair involving infrarenal AXC. This 
difference indicates that suprarenal AXC causes more severe 
renal damage than that caused by infrarenal AXC.
Results of our study should be considered in light of its 
limitations. For instance, the observed AKI was not severe in 
most cases; it was stage 2 in all but one patient. Moreover, the 
elevation in urinary L-FABP was transient; it did not persist 
after surgery, leaving some doubt as to the degree of kidney 
injury that had occurred. We also did not take into account any 
differences in anesthesia. Patients who underwent open repair 
received sevoflurane with remifentanil and epidural anesthe-
sia; patients who underwent EVAR received sevoflurane with 
remifentanil but not epidural anesthesia. Furthermore, various 
vasoactive drugs were administered during open repair but 
not during EVAR. It is possible that either of the anesthesia 
methods affected the renal circulation. However, Peyton et al. 
[34] reported no significant effect of epidural anesthesia on 
renal complications after major abdominal surgery. There-
fore, we believe that our anesthesia methods had little, if any, 
effect on our study outcomes.
In conclusion, our study highlights urinary L-FABP as a 
sensitive biomarker of AKI in patients treated with abdomi-
nal aortic aneurysm repair. Preoperative urinary L-FABP can 
predict postoperative AKI, especially in patients treated with 
EVAR. Urinary L-FABP at 2 h post-AXC can predict post-
operative AKI, in patients treated with open repair. In light of 
these results, we can expect perioperative monitoring of uri-
nary L-FABP to become standard practice for AKI detection 
in patients treated with abdominal aortic aneurysm repair.
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